Key Dates

Related Announcements

• May 09, 2022 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional). See NOFO PAR-22-167.

Issued by

National Center for Advancing Translational Sciences (NCATS)

Purpose

This Notice alerts potential applicants changes to Part 2, Sections III.

Part 2. Full Text of Announcement

Section III. Eligibility Information

Only the statements with the changes shown in bold italics are described here. Other statements in this section remain unchanged.

1. Eligible Applicants

Eligible Organizations

Currently Reads:

For both UG3 and UH3 Phases, an application must involve investigators (as PDs/PIs or Co-investigators) who are from prime or partnering organizations where there are currently active CTSA Program hubs as of the due date of the application. Applicants must be from at least 3 eligible organizations and may choose one of the following options:

Option 1 – The UG3/UH3 must include investigators representing at least three different currently active CTSA Program hubs as of the due date of the application.

Option 2 – The UG3/UH3 application must involve investigators from at least two different currently active CTSA Program hubs and one or more currently active organizations from the participating NIH ICOs listed below, as of the due date of the application. For this option, the contact PD/PI named on the application must be an investigator from a prime or partnering organization where there is currently an active CTSA Program hub as of the due date of the application.

A CTSA Program hub is defined as a UL1 award with a linked KL2 award and an optional TL1 award or a UM1 award. A hub that is in extension status is not considered a currently active CTSA hub (please see CTSA Program Directory). A CTSA Program hub includes the prime recipient organization of the CTSA Program hub UL1 or UM1 award, as well as any organizations listed as partners in the CTSA Program hub UL1 or UM1 awards. Please see the definition of partnering organizations in PAR-18-940 and PAR-21-293. For option 2, the NIH program organizations of participating ICOs described below include only the prime recipient organization of the NIH Program award. If the collaboration involves the recipient organization and partnering organization of the same UL1 award, UM1 award or participating NIH Program award, these organizations are considered as a single eligible organization for the purpose of meeting the minimum number of eligible organizations as described above. If the NIH program organizations of participating ICOs described below are partnering organizations of the CTSA Program hub UL1 or UM1 awards, these organizations are not considered as a single eligible organization for the purpose of meeting the minimum number of eligible organizations as described above. Interested applicants must ensure with each of the collaborating CTSA hub and NIH Program organizations the current funding status as of the due date of the application. Please consult with the prime recipient organization of the CTSA Program hub UL1 or UM1 awards and prime recipient organizations of NIH program awards of participating ICOs described below.

Modified to Read (changes shown in bold italics):

Only active CTSA Hub prime and partnering organizations are eligible to apply.  For both UG3 and UH3 Phases, an application must involve investigators (as PDs/PIs or Co-investigators) who are from prime or partnering organizations where there are currently active CTSA Program hubs as of the due date of the application. Applicants must be from at least 3 eligible organizations and may choose one of the following options:

Option 1 – The UG3/UH3 must include investigators representing at least three different currently active CTSA Program hubs as of the due date of the application.

Option 2 – The UG3/UH3 application must involve investigators from at least two different currently active CTSA Program hubs and one or more currently active organizations from the participating organizations and NIH ICOs listed below, as of the due date of the application. For this option, the contact PD/PI named on the application must be an investigator from a prime or partnering organization where there is currently an active CTSA Program hub as of the due date of the application.

A CTSA Program hub is defined as a UL1 award with a linked KL2 award and an optional TL1 award or a UM1 award. A hub that is in extension status is not considered a currently active CTSA hub (please see CTSA Program Directory). A CTSA Program hub includes the prime recipient organization of the CTSA Program hub UL1 or UM1 award, as well as any organizations listed as partners in the CTSA Program hub UL1 or UM1 awards. Please see the definition of partnering organizations in PAR-18-940 and PAR-21-293. For option 2, the FDA program and NIH program organizations of participating ICOs described below include only the prime recipient organization of the FDA program and NIH Program award. If the collaboration involves the recipient organization and partnering organization of the same UL1 award, UM1 award or participating FDA Program and NIH Program award, these organizations are considered as a single eligible organization for the purpose of meeting the minimum number of eligible organizations as described above. If the FDA program and NIH program organizations of participating ICOs described below are partnering organizations of the CTSA Program hub UL1 or UM1 awards, these organizations are not considered as a single eligible organization for the purpose of meeting the minimum number of eligible organizations as described above. Interested applicants must ensure with each of the collaborating CTSA hub, FDA program and NIH Program organizations the current funding status as of the due date of the application. Please consult with the prime recipient organization of the CTSA Program hub UL1 or UM1 awards and prime recipient organizations of FDA program and NIH program awards of participating ICOs described below.

Eligible Individuals (Program Director/Principal Investigator)

Currently Reads:

The contact PD/PI must be an investigator from a prime or partnering organization where there is currently an active CTSA Program hub as of the due date of the application. Investigators who are not from CTSA hubs (such as investigators who are from a participating organization supported by NIH ICOs and/or external stakeholder), butwho wish to bring an innovative project to the CTSA Program, can co-direct a project using the multiple PD/PI option in collaboration with a contact PD/PI.

Modified to Read (changes shown in bold italics):

The contact PD/PI must be an investigator from a prime or partnering organization where there is currently an active CTSA Program hub as of the due date of the application. Investigators who are not from CTSA hubs (such as investigators who are from a participating organization supported by FDA, NIH ICOs and/or external stakeholder), butwho wish to bring an innovative project to the CTSA Program, can co-direct a project using the multiple PD/PI option in collaboration with a contact PD/PI.

All other aspects of the NOFO remain the same.

Inquiries

Please direct all inquiries to:

Soju Chang, M.D., M.P.H.
National Center for Advancing Translational Sciences (NCATS)
Telephone: (301) 827-9206
E-mail: soju.chang@nih.gov